News | August 08, 2025
Biocon Q1 FY26 PAT slips 95% to Rs. 31.4 Cr
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
Cenexi reports an EBITDA breakeven for the quarter
The company reported a 28% year-on-year increase in Q2 revenue to Rs. 220.9 crore
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Aman holds a bachelor’s degree in economics from Boston University and an MBA from Columbia University, New York
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
Subscribe To Our Newsletter & Stay Updated
